JP2004262929A - α−グルコシダーゼ阻害剤 - Google Patents
α−グルコシダーゼ阻害剤 Download PDFInfo
- Publication number
- JP2004262929A JP2004262929A JP2004034320A JP2004034320A JP2004262929A JP 2004262929 A JP2004262929 A JP 2004262929A JP 2004034320 A JP2004034320 A JP 2004034320A JP 2004034320 A JP2004034320 A JP 2004034320A JP 2004262929 A JP2004262929 A JP 2004262929A
- Authority
- JP
- Japan
- Prior art keywords
- glucosidase
- extract
- glucosidase inhibitor
- obesity
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title claims abstract description 15
- 239000003888 alpha glucosidase inhibitor Substances 0.000 title claims abstract description 15
- 208000008589 Obesity Diseases 0.000 abstract description 10
- 235000020824 obesity Nutrition 0.000 abstract description 10
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 8
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 244000081822 Uncaria gambir Species 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 241001080798 Polygala tenuifolia Species 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000008820 moutan cortex Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000885593 Geisha Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- -1 defoamers Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 235000006020 Acacia catechu Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000001560 acacia catechu Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
α−グルコシダーゼは、消化管での糖質の分解を触媒する酵素であり、その働きを阻害すると、糖質の分解が抑制または遅延され、糖質の吸収を抑制することができる。したがって、α−グルコシダーゼ阻害剤は食後の過血糖を顕著に抑制することから、糖尿病、肥満などの予防あるいは改善に有効である。
本発明の目的は、長期間継続的に服用しても安全かつ効果的な、α−グルコシダーゼ阻害剤を提供することにある。
【解決手段】
ガイジチャ、ボタンピおよびオンジからなる群から選ばれる1種または2種以上を配合することを特徴とするα−グルコシダーゼ阻害剤。
【選択図】 なし
Description
ガイジチャを細切後、10倍量の50%エタノールを加え、約80℃で加熱抽出し、濾過後減圧下でエタノールを留去した後、さらに、濃縮を行うことにより、エキスを得た。
実施例1で得た各生薬エキス(2.5% DMSOで溶解)25μl、リン酸緩衝液(0.25M、pH6.5)125μl、基質溶液50μl(1.4 mM p-nitrophenyl-α-D-glucopyranoside)、酵素溶液(Bacillus stearothermophilus由来α-Glucosidase 1.0 U/ml)50μlを添加し、37℃で30分間反応させた後、波長405 nmにおける吸光度を測定した。なお、各生薬エキスは最終濃度として6.25、12.5、25、50および100μg/mLの各濃度で添加した。
実施例1で得たガイジチャエキス及びオンジエキスのシュークロース投与後の血糖上昇に及ぼす影響を検討した。
ob/obマウス(高血糖を発現するマウス)に実施例1で得たガイジチャエキスを300mg/kg(乾燥エキス換算)の用量で1日1回8週間経口投与した。最終投与日の夕方5時から絶食し、翌日にエーテル麻酔下、後大静脈から採血した。得られた血液から遠心分離法(3000rpm、20℃)により血清を分離し、試験例2に記載した方法に従って血清中のグルコース濃度(mg/dL)を定量した。
Claims (1)
- ガイジチャ、ボタンピおよびオンジからなる群から選ばれる1種または2種以上を配合したことを特徴とするα−グルコシダーゼ阻害剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004034320A JP4706174B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003035983 | 2003-02-14 | ||
JP2003035983 | 2003-02-14 | ||
JP2004034320A JP4706174B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004262929A true JP2004262929A (ja) | 2004-09-24 |
JP2004262929A5 JP2004262929A5 (ja) | 2007-03-29 |
JP4706174B2 JP4706174B2 (ja) | 2011-06-22 |
Family
ID=33133965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004034320A Expired - Fee Related JP4706174B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4706174B2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012502115A (ja) * | 2009-11-05 | 2012-01-26 | コリア インスティテュート オブ オリエンタル メディシン | インフルエンザウイルス由来疾病の予防又は治療用組成物 |
CN103565951A (zh) * | 2013-10-26 | 2014-02-12 | 安徽中医药高等专科学校 | 一种牡丹皮饮片趁鲜切制方法 |
EP3023103A1 (en) * | 2014-11-19 | 2016-05-25 | Korea Institute of Oriental Medicine | Pharmaceutical composition for anti-obesity comprising complex extracts including Saururi chinensis Baill. extract, Curcumae longae rhizoma extract and Polygalae radix extract |
CN114159498A (zh) * | 2022-01-07 | 2022-03-11 | 大连理工大学 | 一种牡丹皮提取物的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59216884A (ja) * | 1983-05-24 | 1984-12-06 | Osaka Chem Lab | タンニン画分特にカテキン化合物高率抽出法 |
JPH04139179A (ja) * | 1990-10-01 | 1992-05-13 | Tsumura & Co | キサントン類を有効成分とするアルドースリダクターゼ阻害剤 |
JPH04139180A (ja) * | 1990-10-01 | 1992-05-13 | Tsumura & Co | 新規キサントン類および該キサントン類を有効成分とするアルドースリダクターゼ阻害剤 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
EP0956867A1 (de) * | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus |
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
-
2004
- 2004-02-12 JP JP2004034320A patent/JP4706174B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59216884A (ja) * | 1983-05-24 | 1984-12-06 | Osaka Chem Lab | タンニン画分特にカテキン化合物高率抽出法 |
JPH04139179A (ja) * | 1990-10-01 | 1992-05-13 | Tsumura & Co | キサントン類を有効成分とするアルドースリダクターゼ阻害剤 |
JPH04139180A (ja) * | 1990-10-01 | 1992-05-13 | Tsumura & Co | 新規キサントン類および該キサントン類を有効成分とするアルドースリダクターゼ阻害剤 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
EP0956867A1 (de) * | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus |
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012502115A (ja) * | 2009-11-05 | 2012-01-26 | コリア インスティテュート オブ オリエンタル メディシン | インフルエンザウイルス由来疾病の予防又は治療用組成物 |
US8591962B2 (en) | 2009-11-05 | 2013-11-26 | Korea Institute Of Oriental Medicine | Composition for preventing and treating influenza-virus-induced diseases |
CN103565951A (zh) * | 2013-10-26 | 2014-02-12 | 安徽中医药高等专科学校 | 一种牡丹皮饮片趁鲜切制方法 |
EP3023103A1 (en) * | 2014-11-19 | 2016-05-25 | Korea Institute of Oriental Medicine | Pharmaceutical composition for anti-obesity comprising complex extracts including Saururi chinensis Baill. extract, Curcumae longae rhizoma extract and Polygalae radix extract |
CN114159498A (zh) * | 2022-01-07 | 2022-03-11 | 大连理工大学 | 一种牡丹皮提取物的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4706174B2 (ja) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2334523C2 (ru) | Композиции для лечения ожирения и ассоциированного метаболического синдрома | |
KR100934955B1 (ko) | 약학적 조성물 및 그 이용 방법 | |
JP4929611B2 (ja) | リパーゼ阻害剤 | |
Dewi et al. | In vitro study of Myristica fragrans seed (Nutmeg) ethanolic extract and quercetin compound as anti-inflammatory agent | |
RU2657757C2 (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
JP5609834B2 (ja) | リパーゼ阻害剤 | |
WO2007083594A1 (ja) | 緩下剤及びこれを含む食品 | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
JP2006514041A (ja) | 混合生薬材を用いた肥満抑制用組成物 | |
JP4982946B2 (ja) | リパーゼ阻害剤 | |
JP5310781B2 (ja) | リパーゼ阻害剤 | |
JP2009137920A (ja) | グリコーゲンホスホリラーゼ阻害剤 | |
JP4547892B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP4604506B2 (ja) | α−グルコシダーゼ阻害剤 | |
JPH09241157A (ja) | リソスペルメートb含有肝臓保護作用医薬組成物 | |
KR100773246B1 (ko) | 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물 | |
JP2003226650A (ja) | 医薬用組成物 | |
JP2014155489A (ja) | サルトリイバラ葉抽出物を含有する糖尿予防及び治療用の組成物 | |
JP4779316B2 (ja) | ジコッピ配合モノアミン再取り込み阻害剤 | |
JP4892833B2 (ja) | 脂肪吸収抑制剤 | |
JPWO2004039388A1 (ja) | α−グルコシダーゼ阻害剤 | |
JP4381585B2 (ja) | 医薬用組成物 | |
JP2004168767A (ja) | α−グルコシダーゼ阻害剤 | |
JP5380930B2 (ja) | 睡眠改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070207 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101001 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110215 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110228 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140325 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |